Halozyme Therapeutics HALO Current Debt
Current Debt at other companies
Other financials
Where this comes from
Reported directly by Halozyme Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:LongTermDebtCurrent.
The official record: Halozyme Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about Halozyme Therapeutics's current debt.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Halozyme Therapeutics's current debt?
- Halozyme Therapeutics (HALO) reported current debt of $208.74M in Q1 2026.
- What is the long-term trend for Halozyme Therapeutics's current debt?
- Over 5 years (2020 to 2025), Halozyme Therapeutics's current debt has grown at a -100.0% compound annual growth rate (CAGR), from $397.23M to $0.
- What does current debt mean?
- The amount of long-term debt that must be paid back within one year.
- How do you interpret current debt?
- A high or increasing amount indicates significant near-term cash outflows, which may pressure liquidity if not managed through refinancing.
- How does current debt compare across companies?
- Used to evaluate short-term debt service capacity and refinancing risk relative to industry peers.